- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07613593
INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease (INCLUDE-CKD)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
- Retrospective: ~450-500 existing users + matched controls(24 months data).
- Comparison with entire WKC CKD population
- Prospective: ~500-550 new users + matched controls (6 months).
- Exploratory: ~500 dialysis or pre transplant MyRenalCare users (no matched controls).
- Qualitative: 15-25 patients + 10-15 staff.
Beskrivelse
Inclusion Criteria:
5.1.1 Inclusion criteria - MyRenalCare users (retrospective and prospective cohorts)
Adults will be eligible for inclusion in the MyRenalCare cohorts if they meet all of the following:
- Aged 18 years or over.
- Under the care of the Wessex Kidney Centre
- Registered with, or offered and subsequently enrolled onto, the MyRenalCare platform during the defined retrospective or prospective periods.
- Able to understand study information and, where applicable, provide informed consent for use of their data for research purposes.
Specific CKD stage definitions and thresholds (e.g. based on eGFR, albuminuria or uPCR) will be documented in the study manual to ensure consistent application.
5.1.2 Inclusion criteria - matched usual care controls
Adults will be eligible for inclusion in the matched control cohorts if they meet all of the following:
- Aged 18 years or over.
- Under the care of the Wessex Kidney Centre for chronic kidney disease.
- Not registered with or using MyRenalCare at any point during the relevant observation period.
- Have sufficient clinical and administrative data available in the renal electronic patient record to enable matching and outcome assessment.
Controls will be identified retrospectively from the renal electronic patient record and matched to MyRenalCare users using a predefined matching strategy.
5.1.3 Inclusion criteria - qualitative interview participants (patients and staff)
Patients will be eligible to take part in the qualitative interview component if they meet all of the following:
- Aged 18 years or over.
- Currently using, or recently offered, the MyRenalCare platform as part of their CKD care at the Wessex Kidney Centre.
- Able to understand spoken and written English to the extent required for participation in an interview.
- Able and willing to provide written informed consent for participation in a recorded interview.
- Belong to a demographic or clinical subgroup of interest for the study (e.g. varying age, ethnicity, CKD stage, or digital engagement level), as part of purposive sampling to support diversity and equity analysis.
Clinical staff will be eligible if they meet all of the following:
- Employed by PHU or working in direct partnership with the Wessex Kidney Centre.
- Directly involved in the care of patients with chronic kidney disease and/or in the implementation or support of MyRenalCare.
- Able and willing to provide informed consent for a recorded interview.
- Able to reflect on experiences and observations relevant to the delivery, uptake, or equity implications of digital health in CKD.
Exclusion Criteria:
- Patients with acute kidney injury without established chronic kidney disease.
- Patients with a very limited life expectancy where participation in routine digital monitoring is not appropriate, as judged by the clinical team.
- Patients who have previously indicated that they do not wish their routinely collected clinical data to be used for research where such opt-out applies to this study.
- Patients who are unable to be identified reliably in the available data sources (for example, inconsistent or missing key identifiers).
- Any other situation where, in the opinion of the responsible clinician, participation in the study processes (including data use) would be inappropriate or unduly burdensome.
- Clinical staff who are not directly involved in the care of patients with chronic kidney disease or in the implementation of the MyRenalCare platform.
- Staff members currently on extended leave or unable to participate during the data collection period.
- Individuals who do not wish to have their views included in recorded interview transcripts or are unable to provide informed consent for participation.
- Any situation where, in the opinion of the study team or the individual's manager, participation would be inappropriate or burdensome due to role, availability, or conflict of interest.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Existing MyRenalCare users (retrospective cohort)
Adults who were already registered and actively using MyRenalCare at the start of the retrospective observation period.
Data will be collected retrospectively from their routine use of the platform.
|
Study is non-interventional.
Andre navn:
|
|
New MyRenalCare users (prospective cohort)
Adults who are newly offered and enroll onto MyRenalCare during the defined recruitment window.
Participants will use the platform as part of routine care, and their engagement will be prospectively monitored.
|
Study is non-interventional.
Andre navn:
|
|
Matched usual care controls
Adults with CKD receiving standard care at the Wessex Kidney Centre who are not enrolled onto MyRenalCare.
These participants receive usual clinical care without access to the MyRenalCare platform.
|
Study is non-interventional.
Andre navn:
|
|
Patients and staff participating in qualitative interviews (qualitative cohort)
A subset of MyRenalCare users (both retrospective and prospective) and clinical staff involved in their care who are invited to take part in interviews about their experiences with MyRenalCare.
|
Study is non-interventional.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary
Tidsramme: 12 months
|
Outcome measure 1: Number and proportion of MyRenalCare users by age, sex, ethnicity and Index of Multiple Deprivation quintile, compared with the CKD population under Wessex Kidney Centre care.
Prevalence ratios will also be calculated.
|
12 months
|
|
Primary
Tidsramme: 12-months
|
Outcome measure 2: Composite digital adherence score (0-100) for MyRenalCare users, combining log-in frequency, completeness of blood pressure and symptom entries, use of secure messaging and duration of sustained use. Analyses stratified by age, sex, ethnicity and deprivation. |
12-months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Secondary
Tidsramme: 12-months
|
Outcome measure1: Number of unplanned and planned hospital admissions for MyRenalCare users compared with matched usual-care controls.
|
12-months
|
|
Secondary
Tidsramme: 12-months
|
Outcome measure 2: Number of outpatient visits (renal and non-renal) for MyRenalCare users compared with matched usual-care controls.
|
12-months
|
|
Secondary
Tidsramme: 12-months
|
Outcome measure 3: CKD progression, measured by change in eGFR, movement between CKD stages, and initiation of kidney replacement therapy for MyRenalCare users versus matched controls.
|
12-months
|
|
Secondary
Tidsramme: 12-months
|
Outcome measure 4: NHS healthcare costs per patient-year for MyRenalCare users compared with matched usual-care controls, including inpatient, outpatient, emergency and relevant community or virtual care contacts.
|
12-months
|
|
Secondary
Tidsramme: 12-months
|
Outcome measure 5: Estimated patient travel-related CO₂ emissions for renal care appointments for MyRenalCare users versus matched usual-care controls, based on travel distance and mode.
|
12-months
|
|
Secondary
Tidsramme: 12-months
|
Outcome measure 6: Themes from qualitative interviews with patients and staff on MyRenalCare usability, support needs, barriers and facilitators to digital engagement.
|
12-months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Patologiske prosesser
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Kronisk sykdom
- Sykdomsattributter
- Nyreinsuffisiens
- Patologiske tilstander, tegn og symptomer
- Nyresvikt, kronisk
Andre studie-ID-numre
- PHU/2024/28
- NIHR510403 (Annen identifikator: NIHR - 2025/400 i4i FAST Commissioned)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kronisk nyre sykdom
-
Zhen LiPåmelding etter invitasjonSamtidig pancreas-Kidney-transplantasjonKina
-
Clínica de Oftalmología de Cali S.AFullførtMeibomian kjerteldysfunksjon | Eyes Dry ChronicColombia
-
University of MiamiHar ikke rekruttert ennåØyesykdommer | Tørre øyne | Eyes Dry ChronicForente stater
-
Southern College of OptometryRekrutteringØyesykdommer | Tørre øyne | Eyes Dry ChronicForente stater
-
CHU de ReimsHar ikke rekruttert ennåFluidrespons i tidlig transplantasjonsperiode etter KidneyFrankrike
-
Chung Shan Medical UniversityNational Science and Technology Council, TaiwanHar ikke rekruttert ennåFedme type 2 diabetes mellitus | Metabolsk dysfunksjon-assosiert Steatotisk leversykdom | Kardiovaskulær-Kidney-metabolsk syndromTaiwan
-
University Hospital, Basel, SwitzerlandHar ikke rekruttert ennåKardiovaskulær-Kidney-metabolsk syndrom | Cradiovascular-Kidney-lever-metabolsk (CKLM) syndromSveits
-
Children's Oncology GroupRekrutteringFase I Mixed Cell Type Kidney Wilms Tumor | Fase II Mixed Cell Type Kidney Wilms Tumor | Fase III Mixed Cell Type Kidney Wilms Tumor | Fase IV Mixed Cell Type Kidney Wilms TumorForente stater, Canada, Australia
-
Camille N. Kotton, MDKamada, Ltd.; University of Texas Southwestern Medical CenterRekrutteringCytomegalovirus | Nyretransplantasjon; Komplikasjoner | Organtransplantasjon | Levertransplantasjonskomplikasjoner | Samtidig lever-Kidney-transplantasjon; KomplikasjonerForente stater
-
Alcon ResearchFullført
Kliniske studier på Non-Interventional Study
-
AstraZenecaFullførtBrystkreft | Onkologi | EpidemiologiAlgerie
-
Mayo ClinicRekrutteringOndartet fast neoplasma | Neoplasma i hematopoetisk og lymfatisk systemForente stater
-
Ohio State University Comprehensive Cancer CenterLilly FoundationRekrutteringAnatomisk stadium IV brystkreft AJCC v8 | Avansert brystkarsinom | Metastatisk brystkarsinomForente stater
-
Mayo ClinicNational Cancer Institute (NCI)Påmelding etter invitasjonBarrett Esophagus | Esophageal adenokarsinomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI); Merck Sharp & Dohme LLCRekrutteringOndartet fast neoplasma | Neoplasma i hematopoetisk og lymfatisk systemForente stater
-
Roswell Park Cancer InstituteRekrutteringSigarettrøykerelatert karsinomForente stater
-
Children's Oncology GroupHar ikke rekruttert ennåHematopoietisk og lymfatisk neoplasma i barndommen | Malignt solid neoplasma i barndommen
-
Ohio State University Comprehensive Cancer CenterAmerican Association for Cancer ResearchRekrutteringAnatomisk stadium I brystkreft AJCC v8 | Anatomisk stadium II brystkreft AJCC v8 | Anatomisk stadium III brystkreft AJCC v8 | Brystkarsinom | Hormonreseptorpositivt brystkarsinomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI)RekrutteringOndartet fast neoplasma | Neoplasma i hematopoetisk og lymfatisk systemForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI)Har ikke rekruttert ennåEndometriekarsinomForente stater